Drug interaction study: does rifampicin change levels of experimental medicine BI 425809?

NCT ID NCT03082183

Completed Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 trial enrolled 16 healthy men to see how the antibiotic rifampicin affects the levels of an experimental drug called BI 425809 (iclepertin) in the blood. Participants took BI 425809 alone and then again after several days of rifampicin. The study measured drug concentrations to understand any interaction, which helps guide future dosing in patient trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rifampicin and BI 425809 (iclepertin)
What this could lead to: If successful, this study could help determine the right dose of BI 425809 when taken with rifampicin, supporting future trials for conditions like cognitive impairment.
What could go wrong: This is a very early, small study in healthy volunteers, not patients. It only looks at drug levels, not whether the drug works for any disease. Results may not apply to people with medical conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

Humanpharmakologisches Zentrum Biberach

Biberach, 88397, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.